MEET OUR TEAM

Chuck Peipher, Managing Director, specializes in helping biopharmaceutical companies develop innovative pricing and market access strategies. He provides brand management counsel and contributes to a wide array of strategic growth initiatives. Chuck helps our clients achieve success in early launch planning and commercial preparedness, clinical pipeline development, and global business consulting.

Chuck has more than 25 years of corporate and consulting experience, including helping to build three life-science based businesses. Chuck’s foundation of experience was gained through his time with AstraZeneca with a variety of specialty care experiences – from the company’s global market-leading mental health drug Seroquel to its first orphan drug (Caprelsa for thyroid cancer). He had senior roles in brand management, healthcare provider marketing, and pricing and market access while also supporting major business development efforts. Chuck’s last position with AstraZeneca was leading the Global Pricing and Market Access team for specialty care support oncology, respiratory, infection, and CNS therapeutic areas.  

As part of MIRADOR Global, Fusun Sevgen partners with clients on developing marketing, pricing, and market access strategies, supporting drug commercialization, new launches, and other strategic initiatives. Fusun is a strategic leader with a track record for developing marketing and access strategies across the product lifecycle, in particular the ability to transform scientific evidence and customer insights into strategies and resources that deliver value to physicians, patients, and payers. She is passionate about developing and supporting individuals and teams with whom she works to achieve growth and success.

Fusun has more than 25 years of pharma industry experience spanning marketing, business management, and sales with deep understanding of global markets, including the U.S., Europe, and Asia. During her career at AstraZeneca, Fusun has had Product Manager, Marketing Manager, and Brand Director roles responsible for developing and implementing launch plans for a range of brands in Europe, Asia and the U.S. She was also Global Pricing and Market Access Director for several brands, responsible for developing payer strategies and resources.

Chelsea Cooper provides Medical Affairs insight into the development of commercial brand strategies and activities; researches and interprets local, regional, and global competitive landscapes; supports the implementation and delivery of a variety of external stakeholder engagements such as advisory boards, roundtable meetings, market research, regional meetings, and Congress activities; and supports the development of medical and sales training materials in preparation for launch.

Chelsea has 15 years of experience in pharma and pharmaceutical consulting. This includes roles in Global Medical Affairs, Promotional Regulatory Affairs, Medical Communications, Speaker Training, and Sales Training. Her core expertise is providing both strategic and tactical Medical Affairs support to biopharma companies with assets that are approaching and/or active in clinical development, including development of competitive TPP/C documents, competitive landscape assessment, portfolio and/or asset assessment and prioritization, payer evidence gap analysis, HEOR project management, Medical Affairs launch planning, and content development for external stakeholder engagement activities.

Rebecca Shindel manages projects ranging from data strategy to claims data analysis to market research, where each project is customized to the client’s needs. Looking at strategy holistically, Rebecca uses several different methodologies to help clients with market sizing, forecasting, pipeline and landscape analysis, target product profile development, and custom market research to refine launch strategies. She also has expertise in creating, customizing, and adapting content to drive sales and marketing efforts – always looking for ways that content can create connections that help drive financial results.

Rebecca has more than 15 years of marketing, sales, operations, and communications roles in both pharmaceuticals and banking. This includes experience in project management, marketing, market research, training, and forecasting and analytics. She has worked with diverse market leaders including AstraZeneca, Alfred I. DuPont Hospital for Children, and Capital One Bank.

Thomas Ross, Executive Director of Commercial Strategy is a veteran of the pharmaceutical industry with over 27 years on the manufacturer side. With roles in strategic planning, market research, secondary data analytics, brand forecasting, competitive intelligence, and performance assessment across all customer segments and various therapeutic areas Tom brings a broad perspective to all his engagements. Tom has worked with brands in all phases of the product life-cycle including pre-launch, multiple brand and indication launches, growth phase and Loss of Exclusivity. A former AstraZeneca executive, Tom lead the US CVMD Insights & Analytics team and was a member of the US Cardiovascular Metabolic Disease leadership team.

Kaylor has 30+ years of bio-pharmaceutical industry experience.  He has held leadership roles in Marketing, Sales, Managed Markets, Key Account Management, and Medical Affairs.  This has included cross functional team leader responsibilities for both early-stage commercial development medicines and in-line flagship brands.  His experience includes 20+ years in oncology working on ten brands including targeted and hormonal therapies, immuno-oncology, and chemotherapy. 

In addition, he has had leadership roles on primary care brands treating cardiovascular disease, diabetes, and metabolic disorders.  Kaylor has direct patient interaction experience via practicing pharmacy for 10+ years at a large teaching hospital in Philadelphia primarily focusing on cardiovascular critical care and in-patient oncology. He currently is a volunteer conducting medical screening and administering Covid 19 immunizations at clinics in his community.

His unique skill set combines science and business talents in order to bridge the gaps that often exist between these two disciplines.  Forward-looking strategic thinking, combined with a high-bar for operational excellence, positions him to provide Mirador Global clients with outstanding commercialization support for early and late-stage oncology assets.

Kaylor is a graduate of the Philadelphia College of Pharmacy and Science (Pharmacy) and Saint Joseph’s University (MBA).  He is also a licensed immunizing pharmacist in multiple states. 

Lizzie is an innovative and accomplished global pricing and market access expert with a deep understanding of payer needs and experience in the design and development of robust pricing and market access strategies to drive differentiated product value. With excellent communication and leadership skills she engages collaboratively across multiple stakeholders to identify opportunities and develop clear insights, strategies and recommendations.

Lizzie has 20+ years pharmaceutical industry experience at AstraZeneca, Allergan (now AbbVie) and GSK in both global and marketing company roles. As a global pricing and market access director she has led the cross functional development of payer evidence, value propositions and pricing and market access strategy for assets in phase 2/3 development predominantly in nephrology/kidney disease and cardiovascular disease and provided support through multiple investment decisions. She has also developed and led a comprehensive payer advisory board program across multiple payer archetypes and markets including US, EU, AsiaPac and LatAm and facilitated the integration of key insights across both clinical and commercial teams. Furthermore, Lizzie has also worked on discreet projects for products in immunology, rare and orphan diseases and NASH.

Karin Turturro-Iuzzini, Vice President of Global Commercial Strategy, will utilize her decades of experience to support our clients in early phase commercialization strategy, forecasting, asset valuation support, payer reimbursement, risk assessment and mitigation, and portfolio/product opportunity assessment and prioritization – all leading up to launch planning.

Karin brings more than 20 years of biopharmaceutical experience to COEUS. She has had great success in building and leading award-winning sales teams, creating dynamic learning and development curricula, and designing and executing marketing strategies, including new product planning. Karin’s collaborative and communicative leadership has driven the success of her cross-functional teams in pre-launch, launch, and post-launch settings. Karin has enjoyed learning and working within many therapeutic areas, including oncology, hematology, rare disease, CNS, respiratory, and cardiovascular – all while keeping a patient-centric vision and approach.

Bindul Turakhia specializes in helping biopharmaceutical companies commercialize their products by putting them in the ideal position to optimize their opportunity and increase their impact. Bindul has over 25 years of operations and program leadership experience in the pharma, healthcare, and financial services industries. His approach has always been to implement fit-for-purpose frameworks to effectively organize, align, and lead cross-functional teams toward strategic goals.

Bindul brings an abundance of product launch experience across many therapeutic areas, including oncology, specialty medicines, and primary care; he and his teams have led over 70 new product launches and line extensions. The empirical knowledge gained across these launches has helped him develop frameworks and processes to determine both the opportunities for success as well as the potential obstacles to navigate and address to create maximum impact for a brand at launch and beyond. Prior to joining MIRADOR Global, Bindul held senior leadership roles at boutique consulting firms developing launch strategies and execution plans for biopharma clients to successfully bring their therapies to patients.

As a Michele Duffy, Vice President of Commercialization and Access, will leverage her extensive experience to support our clients in market access strategy, pricing, reimbursement, commercialization, and launch strategy. She has worked across a breath of indications, most notably cardiometabolic, renal, oncology,  hepatic and rare diseases. Michele brings more than 18 years of biopharmaceutical experience from her tenure at Merck, where she held several senior level positions within market access. As part of a transformational initiative, she led the Market Access design for Merck’s US based organization.  While there, Michele developed a deep understanding of market access strategy, contracting, reimbursement strategies and evidence generation. Michele has successfully developed and implemented strategies that align with payer needs, optimize pricing models, and improve patient access to critical therapies. She is passionate about helping her clients enhance patient care across multiple diseases while ensuring sustainable business outcomes. Her deep understanding of cross-functional collaboration and her commitment to patient-centric solutions have been instrumental in driving the success of commercialization and market access initiatives in both pre-launch and post-launch environments for her clients.

Devon has over twenty-five years of experience in marketing, marketing research and consulting within the Pharmaceutical and Biotech industries. Devon’s prior roles involved evidenced based consulting strategy incorporating desk research and literature searches, qualitative and quantitative market research, secondary data insights, a various analytic techniques. Her expertise includes a variety of methodologies addressing demand research and forecasting, market landscape research, epidemiology assessments, patient journey and buying processes, segmentation, influence networks and custom methodologies incorporating statistical methods. Assembling and collaborating with cross-functional teams to address client business needs is one of Devon’s core strengths. Devon’s educational background is in Mathematics & Statistics. Her initial role in the industry following graduate school was as a Statistician for a data provider (now part of Symphony Health) integrating and analyzing disparate data sources.

As a consultant with CiTRUS, Sam Dean partners with clients on developing marketing, pricing, and market access strategies, supporting drug commercialization, new launches, and other strategic initiatives. Sam develops primary and secondary insight generation activities to formulate optimized client strategies. He leverages the CiTRUS global advisor network to seek advisement from KOL and Payer experts to provide clients with robust solutions to their needs. Over the past three years, Sam has advised clients with strategies in Cardiology, Oncology, Hematology, Obesity and other Rare Diseases, including work with CAR-T therapy, SCT in HemOnc, and ex vivo SCT gene therapy. In the US he has experience working with Commercial, Medicare and Medicaid payers to develop strategies for launch. Globally he has advised clients on strategy for the GBA, HAS, NICE and other emerging markets. He is passionate about developing and supporting individuals and teams with whom he works to achieve growth and success. Along with strategy and access, his work includes all aspects of project management, client coordination, and advisor recruiting. Sam has been with CiTRUS for 3 years supporting teams in strategy consulting, as well as account management. Sam has an MBA from Case Western Reserve University Weatherhead School of Management and a bachelor’s in Biology from Miami University in Oxford, Ohio.

Kara Clarke is a dedicated Associate Consultant with a passion for healthcare consulting and a commitment to delivering impactful solutions for clients. She brings a strong focus on problem-solving, research, and business analytics to her work, ensuring projects are completed with precision and purpose. Kara’s interest in the healthcare industry was sparked during internships with Mirador Global and Highmark Blue Cross Blue Shield Delaware, where she gained early exposure to the complexities of healthcare systems and consulting. Before joining Mirador, Kara served as a Business Development Consultant at Oracle, where she helped organizations streamline their financial, accounting, and procurement processes. In her role at Mirador Global, Kara is focused on managing complex client deliverables, conducting primary and secondary research, and delivering insights that support commercialization and strategic planning efforts. She is a graduate of Penn State University, where she earned a degree in marketing. Kara lives in Kennett Square, PA, and enjoys yoga, hiking with her dog, and spending time with her family.